An interventional study of Flaxseed and Diet in Type 2 Diabetes Mellitus (T2DM), sponsored by Ondokuz Mayıs University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 19 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Ondokuz Mayıs University · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 342 studies in Diabetes Mellitus, Type 2 with a site in Turkey — 61 open to participants now, 71 under way, 12 of them phase 3. Diabetes Mellitus, Type 2 · Turkey.
Among the 342 studies in Diabetes Mellitus, Type 2 with a site in Turkey, this one is the 231st largest by planned enrollment of the 266 interventional ones that give a count, is one of 26 that started in 2025, is one of 150 with no phase, reaches primary completion later than 49 of the 70 other live ones, and was the 253rd registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →61 of the 342 studies in Diabetes Mellitus, Type 2 with a site in Turkey are open now. Recruiting first, the newest first:
Saglik Bilimleri Universitesi · Sites in Turkey
Ages 18–65
Pamukkale University · Sites in Turkey
Ages 18–65 · Women only
Hatice Zehra FERHATLAR · Sites in Turkey
Ages 18–65
Ankara Medipol University · Sites in Turkey
Ages 18–74
AstraZeneca · Sites in Turkey, United States, Argentina and 8 more countries
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 19 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
342 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 85 · Phase 4 28
First in 2002; this study’s year is marked. 26 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 46 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 100 across the 266 interventional studies, 118 across the 75 observational. Of the 261 that completed or were terminated, 80 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 342 have an industry lead sponsor. The 10 most frequent:
Ondokuz Mayıs University is the lead sponsor of 281 studies on the registry; 64 are open to participants now.
Ondokuz Mayıs University has 4 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
25 of the studies in Diabetes Mellitus, Type 2 with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07847294Ankara Medipol UniversityThe Effectiveness of an Occupation-Based Lifestyle Program in Individuals With Type 2 Diabetes | 2026-11 |
| NCT07659925Baskent UniversityPeriodization-Based Strength Exercise Training in İndividuals With Type 2 Diabetes | 2026-11 |
| NCT07734428Istanbul Bilgi UniversityInflammation and Diabetes: Evaluating Antioxidant Levels | 2026-12-30 |
| NCT07649967Selcuk UniversityValidity and Reliability of Mixed Reality-Based Functional Mobility Tests in Type 2 Diabetes | 2026-12-30 |
| NCT06704672Hoffmann-La RocheClinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus | 2027-01-15 |
Add all 25 to your calendar (.ics) → With an account.
Among the 342 studies in Diabetes Mellitus, Type 2 with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main goal of this clinical trial is to determine the effect of flaxseed added to the diet on biochemical parameters and quality of life in patients with Type 2 diabetes mellitus (T2DM). The main questions it aims to answer are:
Researchers will compare patients with T2DM consume diet added flaxseed to a control group to see if flaxseed effect on biochemical parameters and quality of life.
Participants will:
Adult individuals between the ages of 19-65, with a body mass index (BMI) between 20-35 kg/m2, using oral anti-diabetics and not using insulin will be included in the study. Patients with T2DM who agree to participate in the study will be randomly assigned to the intervention or control group using the simple randomization method. Participants will be followed for 12 weeks. Both groups will receive diet as part of T2DM treatment. Subjects in the intervention group will consume 30 g of ground flaxseed per day in addition to their diet. The participants were asked by the researchers through a face-to-face interview technique to determine their demographic characteristics (age, marital status, education level, employment status, income level, etc.), quality of life short form (SF-36) scale, international physical activity questionnaire (IPAQ) and 3-day food consumption record. A survey form questioning consumption records will be applied at the baseline and end of the study. In addition, routinely monitored biochemical parameters of the patients will be recorded from the hospital system at the baseline and end of the study. Anthometric measurements will be taken and recorded by the researcher in accordance with the method. The data obtained will be evaluated in the SPSS package program.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diet will be planned to patients with T2DM as a part of their medical nutritional therapy. This group will take 30 g/d ground flaxseed within their diet.
Dietary Supplement: Flaxseed · Behavioral: Diet
Diet will be planned to patients with T2DM as a part of their medical nutritional therapy.
Behavioral: Diet
30 g/day for 12 weeks
Diet will be planned to patients with T2DM as a part of their medical nutrition therapy.
Evaluation of the effect of flaxseed on fasting blood glucose (mg/dL)
Time frame: From enrollment to the end of intervention at 12 weeks
Evaluation of the effect of flaxseed on HbA1c (%)
Time frame: From enrollment to the end of intervention at 12 weeks
Evaluation of the effect of flaxseed on total triglyceride (mg/dL)
Time frame: From enrollment to the end of intervention at 12 weeks
Evaluation of the effect of flaxseed on total cholesterol (mg/dL)
Time frame: From enrollment to the end of intervention at 12 weeks
Evaluation of the effect of flaxseed on HDL-cholesterol (mg/dL)
Time frame: From enrollment to the end of intervention at 12 weeks
Evaluation of the effect of flaxseed on LDL-cholesterol (mg/dL)
Time frame: From enrollment to the end of intervention at 12 weeks
Evaluation of the effect of flaxseed on quality of life
Quality of life will be assessed with SF-36. The total score is evaluated separately into two summary scores: the physical component summary (PCS12) and the mental component summary (MCS12). The score of the answers related to the PCS12 is obtained from the factors of general health, role-physical, physical functioning, and bodily pain, and the score of the answers related to the MCS12 is obtained from the factors of social functioning, role-emotional, mental health, and energy/fatigue. Both scores range from 0 to 100, with a higher score representing better health.
Time frame: From enrollment to the end of intervention at 12 weeks
Evaluation of the effect of flaxseed on BMI (kg/m2)
Time frame: From enrollment to the end of intervention at 12 weeks
Evaluation of the effect of flaxseed on waist circumference (cm)
Time frame: From enrollment to the end of intervention at 12 weeks
Evaluation of the effect of flaxseed on waist/hip ratio
Time frame: From enrollment to the end of intervention at 12 weeks
Started Sep 2025 (actual). Primary completion is estimated for May 2027, 20 months after the start.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 20 months is close to that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Apr 2026 → May 2027 and completion May 2026 → May 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Flaxseed